About Senores Pharmaceuticals Limited
Data last updated: 15 December 2025
Senores Pharmaceuticals Limited is a public limited company based in Ahmedabad, Gujarat, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 26 December 2017, the company has been in operation for over 9 years.
Registered with ROC Ahmedabad under CIN L24290GJ2017PLC100263. Listed.
Capital: an authorised share capital of ₹59 Cr and a paid-up capital of ₹46.05 Cr. It is led by directors including Sanjay Shaileshbhai Majmudar and Ashokbhai Vijaysinh Barot.
Last AGM: 18 September 2025. Financial statements filed for year ended 31 March 2025. Office: 1101 To 1103 11Th Floor South Tower One 42 Opp. Jayantilal Park Ambali Bopal Road, Ahmedabad, Gujarat, India – 380054.
As per the financials filed for FY 2025, the company reported a revenue of ₹417.51 Cr, a growth of 92% compared to the previous year.
The company has a workforce of approximately 120 employees as per the latest available data. Its group structure includes 1 subsidiary.
The company is associated with 1 brand - Senores Pharmaceuticals. As per MCA filings, the company has open charges of ₹115.14 Cr and satisfied charges of ₹130.75 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website senorespharma.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered Address1101 To 1103 11Th Floor South Tower One 42 Opp. Jayantilal Park Ambali Bopal Road, Ahmedabad, Gujarat, India – 380054
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24290GJ2017PLC100263, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24290GJ2017PLC100263 | Current |
| U24290GJ2017PTC100263 | Previous |
| U24290GJ2017PLC100263 | Previous |
Associated Brands with Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited operates one associated brand: Senores Pharmaceuticals. These brands represent Senores Pharmaceuticals Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical drugs are manufactured by Senores Pharmaceuticals. | senorespharma.com |
Business Activity of Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited is audited by M/s Pankaj R Shah & Associates (ICAI peer reviewed, certificate valid till 2027-10-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| M/s Pankaj R Shah & Associates (ICAI peer reviewed, certificate valid till 2027-10-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited is currently managed by 13 directors, with 17 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Sanjay Shaileshbhai Majmudar
Also directs:
Senores Pharmaceuticals Limited, Welcast Steels Limited, Aia Engineering Limited and 2 more
|
Director | 10 Feb 2024 | 2 Years 4 Months | Current |
|
Ashokbhai Vijaysinh Barot
Also directs:
Senores Pharmaceuticals Limited, Aviraj Ventures Llp, Di- Cal Pharma Private Limited and 2 more
|
Director | 15 May 2018 | 8 Years 1 Months | Current |
|
Swapnil Jatinbhai Shah
Also directs:
Senores Pharmaceuticals Limited, Ratnatris Pharmaceuticals Private Limited, Espee Therapeutics Llp and 5 more
|
Managing Director | 15 Oct 2021 | 4 Years 8 Months | Current |
|
Naresh Bansilal Shah
Also directs:
Senores Pharmaceuticals Limited
|
Director | 30 Jan 2024 | 2 Years 5 Months | Current |
|
Hemanshu Nitinchandra Pandya
Also directs:
Senores Pharmaceuticals Limited
|
Director | 10 Nov 2023 | 2 Years 7 Months | Current |
| Chetan Bipinchandra Shah | Whole-Time Director | 10 Nov 2023 | 2 Years 7 Months | Current |
Financials of Senores Pharmaceuticals Limited FY 2026 filings available
Senores Pharmaceuticals Limited reported revenue of ₹632.63 Cr (up 58.85% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Revenue from Operations | ₹632.63 Cr | ₹398.25 Cr |
| Other Income | ₹47.06 Cr | ₹19.26 Cr |
| Total Income | ₹679.69 Cr | ₹417.51 Cr |
| Cost of Materials Consumed | ₹114.27 Cr | ₹91.64 Cr |
| Purchases of Stock-in-Trade | ₹137.32 Cr | ₹89.82 Cr |
| Changes in Inventories | ₹7 Lakh | -₹76 Lakh |
| Employee Benefit Expense | ₹112.25 Cr | ₹60.37 Cr |
| Finance Costs | ₹25.03 Cr | ₹21.55 Cr |
| Depreciation & Amortisation | ₹31.25 Cr | ₹16.84 Cr |
| Other Expenses | ₹100.4 Cr | ₹67.48 Cr |
| Total Expenses | ₹520.59 Cr | ₹346.94 Cr |
| Profit Before Exceptional Items & Tax | ₹159.1 Cr | ₹70.57 Cr |
| Exceptional Items | ₹0 | ₹0 |
| Profit Before Tax | ₹159.1 Cr | ₹70.57 Cr |
| Total Tax Expense | ₹37.57 Cr | ₹12.23 Cr |
| Net Profit | ₹121.53 Cr | ₹58.34 Cr |
| attributable to Owners | ₹0 | - |
| attributable to NCI | ₹0 | - |
| Other Comprehensive Income | ₹29.19 Cr | -₹3.53 Cr |
| Total Comprehensive Income | ₹150.72 Cr | ₹54.81 Cr |
| EBITDA (computed) | ₹215.38 Cr | ₹108.96 Cr |
| Basic EPS | ₹26.39 | ₹16.12 |
| Diluted EPS | ₹26.39 | ₹16.12 |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Total Assets | ₹1,603.81 Cr | ₹1,226.86 Cr |
| Non-current Assets | ₹791.38 Cr | ₹504.43 Cr |
| Current Assets | ₹812.43 Cr | ₹722.43 Cr |
| Property, Plant & Equipment | ₹331.37 Cr | ₹198.85 Cr |
| Inventories | ₹89.29 Cr | ₹56.63 Cr |
| Trade Receivables | ₹324.82 Cr | ₹123.88 Cr |
| Cash & Equivalents | ₹45.55 Cr | ₹105.38 Cr |
| Equity (Net Worth) | ₹964.54 Cr | ₹812.24 Cr |
| Equity Share Capital | ₹46.05 Cr | ₹46.05 Cr |
| Borrowings (Non-current) | ₹194.89 Cr | ₹162.46 Cr |
| Borrowings (Current) | ₹132.2 Cr | ₹142.3 Cr |
| Total Debt (computed) | ₹327.09 Cr | ₹304.76 Cr |
| Current Liabilities | ₹424 Cr | ₹240.7 Cr |
| Total Liabilities | ₹639.27 Cr | ₹414.62 Cr |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Operating Cash Flow | ₹62.05 Cr | -₹45.92 Cr |
| Investing Cash Flow | -₹120.56 Cr | -₹429.48 Cr |
| Financing Cash Flow | -₹1.32 Cr | ₹573.14 Cr |
| Capital Expenditure | ₹240.13 Cr | ₹157.52 Cr |
| Free Cash Flow (computed) | -₹178.08 Cr | -₹203.44 Cr |
| Dividends Paid | ₹0 | ₹0 |
| Net Change in Cash | -₹59.83 Cr | ₹97.74 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹175.19 Cr | ₹174.56 Cr | ₹161.76 Cr | ₹137.99 Cr | ₹114.21 Cr | ₹103.02 Cr |
| Other Income | ₹17.67 Cr | ₹3.78 Cr | ₹5.41 Cr | ₹3.36 Cr | ₹11.77 Cr | ₹5.16 Cr |
| Total Income | ₹192.86 Cr | ₹178.34 Cr | ₹167.17 Cr | ₹141.35 Cr | ₹125.98 Cr | ₹108.17 Cr |
| Cost of Materials Consumed | ₹27.05 Cr | ₹36.96 Cr | ₹46.09 Cr | ₹29.38 Cr | ₹20.94 Cr | ₹23.1 Cr |
| Purchases of Stock-in-Trade | ₹35.71 Cr | ₹37.87 Cr | ₹11 Cr | ₹27.55 Cr | ₹29.06 Cr | ₹22.13 Cr |
| Changes in Inventories | ₹3.46 Cr | -₹7.81 Cr | -₹1 Lakh | ₹4.43 Cr | ₹7.46 Cr | -₹4.53 Cr |
| Employee Benefit Expense | ₹30.32 Cr | ₹30.66 Cr | ₹29.62 Cr | ₹21.65 Cr | ₹14.63 Cr | ₹19.01 Cr |
| Finance Costs | ₹8.46 Cr | ₹5.33 Cr | ₹6.19 Cr | ₹5.04 Cr | ₹5.3 Cr | ₹6.16 Cr |
| Depreciation & Amortisation | ₹9.3 Cr | ₹7.85 Cr | ₹8.09 Cr | ₹6 Cr | ₹5.23 Cr | ₹4.2 Cr |
| Other Expenses | ₹31.16 Cr | ₹22.88 Cr | ₹25.55 Cr | ₹20.81 Cr | ₹22.68 Cr | ₹17.63 Cr |
| Total Expenses | ₹145.46 Cr | ₹133.74 Cr | ₹126.53 Cr | ₹114.86 Cr | ₹105.3 Cr | ₹87.69 Cr |
| Profit Before Exceptional Items & Tax | ₹47.4 Cr | ₹44.6 Cr | ₹40.64 Cr | ₹26.49 Cr | ₹20.68 Cr | ₹20.48 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹47.4 Cr | ₹44.6 Cr | ₹40.64 Cr | ₹26.49 Cr | ₹20.68 Cr | ₹20.48 Cr |
| Total Tax Expense | ₹10.73 Cr | ₹11.02 Cr | ₹10.52 Cr | ₹5.31 Cr | ₹2.71 Cr | ₹4.05 Cr |
| Net Profit | ₹36.67 Cr | ₹33.58 Cr | ₹30.12 Cr | ₹21.18 Cr | ₹17.97 Cr | ₹16.43 Cr |
| attributable to Owners | ₹0 | ₹31.66 Cr | ₹32.38 Cr | ₹19.73 Cr | - | ₹17.18 Cr |
| attributable to NCI | ₹0 | ₹1.92 Cr | -₹2.26 Cr | ₹1.45 Cr | - | -₹75.3 Lakh |
| Other Comprehensive Income | ₹41.92 Cr | -₹4.79 Cr | -₹8.4 Cr | ₹47 Lakh | -₹12 Lakh | -₹2.19 Cr |
| Total Comprehensive Income | ₹78.59 Cr | ₹28.79 Cr | ₹21.72 Cr | ₹21.65 Cr | ₹17.85 Cr | ₹14.24 Cr |
| EBITDA (computed) | ₹65.16 Cr | ₹57.78 Cr | ₹54.92 Cr | ₹37.53 Cr | ₹31.21 Cr | ₹30.84 Cr |
| Basic EPS | ₹7.96 | ₹7.29 | ₹6.54 | ₹4.60 | ₹3.81 | ₹5.04 |
| Diluted EPS | ₹7.96 | ₹7.29 | ₹6.54 | ₹4.60 | ₹3.81 | ₹5.04 |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Revenue from Operations | ₹106.09 Cr | ₹38.54 Cr |
| Other Income | ₹66.35 Cr | ₹21.99 Cr |
| Total Income | ₹172.44 Cr | ₹60.53 Cr |
| Cost of Materials Consumed | ₹24.55 Cr | ₹7.26 Cr |
| Purchases of Stock-in-Trade | ₹30.42 Cr | ₹14.67 Cr |
| Changes in Inventories | -₹30 Lakh | -₹4.1 Cr |
| Employee Benefit Expense | ₹38.78 Cr | ₹18.25 Cr |
| Finance Costs | ₹6.98 Cr | ₹6.52 Cr |
| Depreciation & Amortisation | ₹13.23 Cr | ₹3.08 Cr |
| Other Expenses | ₹31.32 Cr | ₹9.74 Cr |
| Total Expenses | ₹144.98 Cr | ₹55.42 Cr |
| Profit Before Exceptional Items & Tax | ₹27.46 Cr | ₹5.11 Cr |
| Exceptional Items | ₹0 | ₹0 |
| Profit Before Tax | ₹27.46 Cr | ₹5.11 Cr |
| Total Tax Expense | ₹7.21 Cr | ₹1.42 Cr |
| Net Profit | ₹20.25 Cr | ₹3.69 Cr |
| Other Comprehensive Income | -₹1 Lakh | -₹23 Lakh |
| Total Comprehensive Income | ₹20.24 Cr | ₹3.46 Cr |
| EBITDA (computed) | ₹47.67 Cr | ₹14.71 Cr |
| Basic EPS | ₹4.40 | ₹1.02 |
| Diluted EPS | ₹4.40 | ₹1.02 |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Total Assets | ₹887.91 Cr | ₹834.09 Cr |
| Non-current Assets | ₹632.27 Cr | ₹422.01 Cr |
| Current Assets | ₹255.64 Cr | ₹412.08 Cr |
| Property, Plant & Equipment | ₹97.92 Cr | ₹46.23 Cr |
| Inventories | ₹9.75 Cr | ₹8.66 Cr |
| Trade Receivables | ₹76.46 Cr | ₹25.69 Cr |
| Cash & Equivalents | ₹32.22 Cr | ₹81.2 Cr |
| Equity (Net Worth) | ₹749.9 Cr | ₹707.96 Cr |
| Equity Share Capital | ₹46.05 Cr | ₹46.05 Cr |
| Borrowings (Non-current) | ₹51.77 Cr | ₹76.26 Cr |
| Borrowings (Current) | ₹19.74 Cr | ₹17.71 Cr |
| Total Debt (computed) | ₹71.51 Cr | ₹93.97 Cr |
| Current Liabilities | ₹69.56 Cr | ₹41.23 Cr |
| Total Liabilities | ₹138.01 Cr | ₹126.13 Cr |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Operating Cash Flow | -₹26.88 Cr | -₹20.4 Cr |
| Investing Cash Flow | -₹19.46 Cr | -₹162.93 Cr |
| Financing Cash Flow | -₹2.64 Cr | ₹532.62 Cr |
| Capital Expenditure | ₹34.86 Cr | ₹49.12 Cr |
| Free Cash Flow (computed) | -₹61.74 Cr | -₹69.52 Cr |
| Dividends Paid | ₹0 | ₹0 |
| Net Change in Cash | -₹48.98 Cr | ₹349.29 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹36.81 Cr | ₹28.76 Cr | ₹35.33 Cr | ₹19.82 Cr | ₹11.86 Cr | ₹9.59 Cr |
| Other Income | ₹22.19 Cr | ₹9.78 Cr | ₹11.36 Cr | ₹8.39 Cr | ₹9.25 Cr | ₹7.19 Cr |
| Total Income | ₹59 Cr | ₹38.54 Cr | ₹46.69 Cr | ₹28.21 Cr | ₹21.11 Cr | ₹16.78 Cr |
| Cost of Materials Consumed | ₹18.36 Cr | ₹3.78 Cr | ₹1 Cr | ₹1.4 Cr | ₹2.81 Cr | ₹1.83 Cr |
| Purchases of Stock-in-Trade | ₹5.1 Cr | ₹11.98 Cr | ₹11 Cr | ₹2.34 Cr | ₹7.46 Cr | ₹2.4 Cr |
| Changes in Inventories | ₹6 Lakh | -₹3.39 Cr | -₹37 Lakh | ₹3.41 Cr | -₹3.54 Cr | ₹1.07 Cr |
| Employee Benefit Expense | ₹11.12 Cr | ₹9.16 Cr | ₹11.59 Cr | ₹6.91 Cr | ₹4.45 Cr | ₹4.92 Cr |
| Finance Costs | ₹1.89 Cr | ₹1.75 Cr | ₹1.58 Cr | ₹1.76 Cr | ₹2.35 Cr | ₹2.7 Cr |
| Depreciation & Amortisation | ₹4.13 Cr | ₹3.58 Cr | ₹3.65 Cr | ₹1.88 Cr | ₹1.27 Cr | ₹75.5 Lakh |
| Other Expenses | ₹5.65 Cr | ₹8.16 Cr | ₹10.59 Cr | ₹6.92 Cr | ₹3.41 Cr | ₹1.78 Cr |
| Total Expenses | ₹46.31 Cr | ₹35.02 Cr | ₹39.04 Cr | ₹24.62 Cr | ₹18.21 Cr | ₹15.46 Cr |
| Profit Before Exceptional Items & Tax | ₹12.69 Cr | ₹3.52 Cr | ₹7.65 Cr | ₹3.59 Cr | ₹2.9 Cr | ₹1.32 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹12.69 Cr | ₹3.52 Cr | ₹7.65 Cr | ₹3.59 Cr | ₹2.9 Cr | ₹1.32 Cr |
| Total Tax Expense | ₹4.21 Cr | ₹87 Lakh | ₹1.22 Cr | ₹89 Lakh | ₹88 Lakh | ₹24.6 Lakh |
| Net Profit | ₹8.48 Cr | ₹2.65 Cr | ₹6.43 Cr | ₹2.7 Cr | ₹2.02 Cr | ₹1.08 Cr |
| Other Comprehensive Income | ₹6 Lakh | ₹3 Lakh | -₹10 Lakh | ₹0 | -₹20 Lakh | ₹6 Lakh |
| Total Comprehensive Income | ₹8.54 Cr | ₹2.68 Cr | ₹6.33 Cr | ₹2.7 Cr | ₹1.82 Cr | ₹1.14 Cr |
| EBITDA (computed) | ₹18.71 Cr | ₹8.85 Cr | ₹12.88 Cr | ₹7.23 Cr | ₹6.52 Cr | ₹4.78 Cr |
| Basic EPS | ₹1.84 | ₹1.98 | ₹1.40 | ₹0.59 | ₹0.39 | ₹0.32 |
| Diluted EPS | ₹1.84 | ₹1.98 | ₹1.40 | ₹0.59 | ₹0.39 | ₹0.32 |
Shareholding Pattern of Senores Pharmaceuticals Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 45.82%, foreign institutional investors hold 3.64%, domestic institutional investors hold 9.61%, retail and other public shareholders hold 40.93% of Senores Pharmaceuticals Limited. The company had 34,126 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 45.82% | 45.80% | 45.80% | 45.78% | 45.77% | 45.76% |
| Public | 54.18% | 54.20% | 54.20% | 54.22% | 54.23% | 54.24% |
| Mar 2026 | Mar 2025 | |
|---|---|---|
| Promoters | 45.82% | 45.77% |
| Public | 54.18% | 54.23% |
| Promoter change (YoY, %pts) | +0.05 | - |
Board & Governance of Senores Pharmaceuticals Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Senores Pharmaceuticals Limited has 12 directors - 4 independent and 3 executive. The board is chaired by Sanjay Shaileshbhai Majmudar.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Sanjay Shaileshbhai Majmudar | Non-Executive - Non Independent Director · Chairperson | 2024-02-10 | 5 |
| Swapnil Jatinbhai Shah | Executive Director · MD | 2021-10-15 | 2 |
| Hemanshu Nitinchandra Pandya | Non-Executive - Non Independent Director | 2023-11-10 | 1 |
| Jitendra Babulal Sanghvi | Non-Executive - Non Independent Director | 2021-11-23 | 1 |
| Chetan Bipinchandra Shah | Executive Director | 2023-11-10 | 1 |
| Deval Rajnikant Shah | Executive Director | 2020-01-01 | 1 |
| Ashokbhai Vijaysinh Barot | Non-Executive - Non Independent Director | 2018-05-15 | 1 |
| Shah Arpit Deepakkumar | Non-Executive - Non Independent Director | 2023-11-10 | 2 |
| Naresh Bansilal Shah | Non-Executive - Independent Director | 2024-01-30 | 1 |
| Manjuladevi Pratul Shroff | Non-Executive - Independent Director | 2024-01-30 | 1 |
| Kalpit Rajesh Gandhi | Non-Executive - Independent Director | 2024-01-30 | 2 |
| Udayan Dileep Choksi | Non-Executive - Independent Director | 2024-03-08 | 4 |
| Committee | Members |
|---|---|
| Audit Committee | Kalpit Rajesh Gandhi (Chairperson), Udayan Dileep Choksi, Naresh Bansilal Shah, Swapnil Jatinbhai Shah |
| Nomination and remuneration committee | Udayan Dileep Choksi (Chairperson), Kalpit Rajesh Gandhi, Sanjay Shaileshbhai Majmudar |
| Stakeholders Relationship Committee | Sanjay Shaileshbhai Majmudar (Chairperson), Kalpit Rajesh Gandhi, Manjuladevi Pratul Shroff, Swapnil Jatinbhai Shah |
| Risk Management Committee | Chetan Bipinchandra Shah (Chairperson), Sanjay Shaileshbhai Majmudar, Swapnil Jatinbhai Shah, Udayan Dileep Choksi |
| Corporate Social Responsibility Committee | Manjuladevi Pratul Shroff (Chairperson), Swapnil Jatinbhai Shah, Ashokbhai Vijaysinh Barot |
Group Structure of Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has 1 subsidiary company. This group structure data is as of FY 2024. The corporate group structure reflects Senores Pharmaceuticals Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Ratnatris Pharmaceuticals Private Limited | U24230GJ2005PTC047394 | - |
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Senores Pharmaceuticals Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Nov 2025 | Hdfc Bank Limited | ₹23 Lakh | Open |
| 26 Jun 2025 | Hdfc Bank Limited | ₹44.6 Lakh | Open |
| 02 May 2025 | Hdfc Bank Limited | ₹35.1 Lakh | Open |
| 13 Feb 2025 | Others | ₹45 Cr | Open |
| 07 Dec 2024 | Hdfc Bank Limited | ₹11.29 Lakh | Open |
Total charge records: 11 View all charges
Employees and EPFO Compliance at Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has a workforce of 120 employees as of Feb 10, 2025.
Employee Count & EPFO Data of Senores Pharmaceuticals Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Senores Pharmaceuticals Limited
GSTIN & GST Filing Data of Senores Pharmaceuticals Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Senores Pharmaceuticals Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Senores Pharmaceuticals Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Senores Pharmaceuticals Limited
MSME Payment Delays by Senores Pharmaceuticals Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Senores Pharmaceuticals Limited
Subsidiaries & Group Companies of Senores Pharmaceuticals Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Senores Pharmaceuticals Limited with ownership details.
MCA Filings & Documents of Senores Pharmaceuticals Limited
MCA Filings & Documents of Senores Pharmaceuticals Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Senores Pharmaceuticals Limited
Frequently Asked Questions about Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited is an active public limited company in the pharma sector based in Ahmedabad, Gujarat, India. It was incorporated on 26 December 2017 (9+ years old) and is registered under CIN L24290GJ2017PLC100263. The company has 120 employees.
Senores Pharmaceuticals Limited reported revenue of ₹417.51 Cr for FY 2025 (up 92.00% YoY).
The current directors of Senores Pharmaceuticals Limited are:
- Sanjay Shaileshbhai Majmudar
- Ashokbhai Vijaysinh Barot
- Swapnil Jatinbhai Shah
- Naresh Bansilal Shah
- Hemanshu Nitinchandra Pandya
- Chetan Bipinchandra Shah
- Kalpit Rajesh Gandhi
- Udayan Dileep Choksi
- Jitendra Babulal Sanghvi
- Arpit Deepakkumar Shah
- Deval Rajnikant Shah
- Manjula Devi Shroff
- Deval Rajnikant Shah
The primary industry of Senores Pharmaceuticals Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Yes, Senores Pharmaceuticals Limited is a listed company.
Senores Pharmaceuticals Limited can be reached at the registered office: 1101 To 1103 11Th Floor South Tower One 42 Opp. Jayantilal Park Ambali Bopal Road, Ahmedabad, Gujarat, India – 380054, or through the website senorespharma.com.